Literature DB >> 23702611

Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City.

Helena B Hansen1, Carole E Siegel, Brady G Case, David N Bertollo, Danae DiRocco, Marc Galanter.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23702611      PMCID: PMC3818282          DOI: 10.1007/s11414-013-9341-3

Source DB:  PubMed          Journal:  J Behav Health Serv Res        ISSN: 1094-3412            Impact factor:   1.505


× No keyword cloud information.
  35 in total

1.  Inequalities in disability-free life expectancy by area deprivation: England, 2001-04 and 2005-08.

Authors:  Michael P Smith; Olugbenga Olatunde; Chris White
Journal:  Health Stat Q       Date:  2010

2.  Prevalence of treated diabetes: Geographical variations at the small-area level and their association with area-level characteristics. A multilevel analysis in Southeastern France.

Authors:  A Bocquier; S Cortaredona; S Nauleau; M Jardin; P Verger
Journal:  Diabetes Metab       Date:  2010-10-25       Impact factor: 6.041

3.  Comparing overdose mortality associated with methadone and buprenorphine treatment.

Authors:  James R Bell; Bethany Butler; Anne Lawrance; Robert Batey; Pia Salmelainen
Journal:  Drug Alcohol Depend       Date:  2009-05-13       Impact factor: 4.492

4.  Epidemiological sociology and the social shaping of population health.

Authors:  Bruce G Link
Journal:  J Health Soc Behav       Date:  2008-12

5.  Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey.

Authors:  Amy Nunn; Nickolas Zaller; Samuel Dickman; Catherine Trimbur; Ank Nijhawan; Josiah D Rich
Journal:  Drug Alcohol Depend       Date:  2009-07-21       Impact factor: 4.492

6.  Integrating buprenorphine treatment into office-based practice: a qualitative study.

Authors:  Declan T Barry; Kevin S Irwin; Emlyn S Jones; William C Becker; Jeanette M Tetrault; Lynn E Sullivan; Helena Hansen; Patrick G O'Connor; Richard S Schottenfeld; David A Fiellin
Journal:  J Gen Intern Med       Date:  2008-12-17       Impact factor: 5.128

7.  The promotion and marketing of oxycontin: commercial triumph, public health tragedy.

Authors:  Art Van Zee
Journal:  Am J Public Health       Date:  2008-09-17       Impact factor: 9.308

8.  Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial.

Authors:  Stephen Magura; Joshua D Lee; Jason Hershberger; Herman Joseph; Lisa Marsch; Carol Shropshire; Andrew Rosenblum
Journal:  Drug Alcohol Depend       Date:  2008-10-18       Impact factor: 4.492

9.  Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS.

Authors:  Peter Lawrinson; Robert Ali; Aumphornpun Buavirat; Sithisat Chiamwongpaet; Sergey Dvoryak; Boguslaw Habrat; Shi Jie; Ratna Mardiati; Azarakhsh Mokri; Jacek Moskalewicz; David Newcombe; Vladimir Poznyak; Emilis Subata; Ambrose Uchtenhagen; Diah S Utami; Robyn Vial; Chengzheng Zhao
Journal:  Addiction       Date:  2008-07-10       Impact factor: 6.526

10.  A practical clinical trial of coordinated care management to treat substance use disorders among public assistance beneficiaries.

Authors:  Jon Morgenstern; Aaron Hogue; Sarah Dauber; Christopher Dasaro; James R McKay
Journal:  J Consult Clin Psychol       Date:  2009-04
View more
  46 in total

1.  Factors associated with buprenorphine versus methadone use in pregnancy.

Authors:  Elizabeth E Krans; Debra Bogen; Gale Richardson; Seo Young Park; Shannon L Dunn; Nancy Day
Journal:  Subst Abus       Date:  2016-02-25       Impact factor: 3.716

2.  The War on Drugs That Wasn't: Wasted Whiteness, "Dirty Doctors," and Race in Media Coverage of Prescription Opioid Misuse.

Authors:  Julie Netherland; Helena B Hansen
Journal:  Cult Med Psychiatry       Date:  2016-12

3.  Understanding interactions of formerly incarcerated HIV-positive men and transgender women with substance use treatment, medical, and criminal justice systems.

Authors:  Nina T Harawa; Bita Amani; Jane Rohde Bowers; Jennifer N Sayles; William Cunningham
Journal:  Int J Drug Policy       Date:  2017-08-09

4.  Integrating Buprenorphine Into an Opioid Treatment Program: Tailoring Care for Patients With Opioid Use Disorders.

Authors:  Soteri Polydorou; Stephen Ross; Peter Coleman; Laura Duncan; Nichole Roxas; Anil Thomas; Sonia Mendoza; Helena Hansen
Journal:  Psychiatr Serv       Date:  2016-10-17       Impact factor: 3.084

5.  Shifting blame: Buprenorphine prescribers, addiction treatment, and prescription monitoring in middle-class America.

Authors:  Sonia Mendoza; Allyssa S Rivera-Cabrero; Helena Hansen
Journal:  Transcult Psychiatry       Date:  2016-08-03

6.  Racial and Ethnic Disparities in Maternal and Infant Outcomes Among Opioid-Exposed Mother-Infant Dyads in Massachusetts (2017-2019).

Authors:  Mary Peeler; Munish Gupta; Patrice Melvin; Allison S Bryant; Hafsatou Diop; Ronald Iverson; Katherine Callaghan; Elisha M Wachman; Rachana Singh; Mary Houghton; Shelly F Greenfield; Davida M Schiff
Journal:  Am J Public Health       Date:  2020-10-15       Impact factor: 9.308

Review 7.  The Syndemic of Opioid Misuse, Overdose, HCV, and HIV: Structural-Level Causes and Interventions.

Authors:  David C Perlman; Ashly E Jordan
Journal:  Curr HIV/AIDS Rep       Date:  2018-04       Impact factor: 5.071

8.  White opioids: Pharmaceutical race and the war on drugs that wasn't.

Authors:  Julie Netherland; Helena Hansen
Journal:  Biosocieties       Date:  2017-06-28

9.  At the Expense of a Life: Race, Class, and the Meaning of Buprenorphine in Pharmaceuticalized "Care".

Authors:  Alexandrea E Hatcher; Sonia Mendoza; Helena Hansen
Journal:  Subst Use Misuse       Date:  2017-11-21       Impact factor: 2.164

10.  Recent Internet Use and Associations with Clinical Outcomes among Patients Entering Addiction Treatment Involved in a Web-Delivered Psychosocial Intervention Study.

Authors:  B Tofighi; A N C Campbell; M Pavlicova; M C Hu; J D Lee; E V Nunes
Journal:  J Urban Health       Date:  2016-10       Impact factor: 3.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.